CompanLunGuard is developing a novel technology solution for the future of critical care medicine (ICU) that enables better nutrition, treatment and reducing nosocomial infection in the ICU; the new approach of the “Personalized Physiological Medicine (PPM)” based on a smart peristaltic enteral feeding tube that is structured from several inflatable balloons used as a multi-sensory platform. LunGuard’s innovative solution, together with the substantial clinical need, is designed to safely block Gastro Esophageal Reflux (GER) and reduce nosocomial infection in the ICU that cause Ventilator Associated Pneumonia (VAP). VAP leads to life risking clinical complications that are unrelated to the initial reason of hospitalization. Clinical complications require complex medical treatment, deteriorate patient conditions and prolong the patient’s length of stay (LOS)
The LunGuard technology brings the optimal platform for future personalized medicine by capturing critical data from different physiological locations e.g. sealing mechanism within the esophagus and Transpulmonary Pressure (TPP) from the respiratory airway; In addition, the system monitors the Dysmotility of the upper Gastrointestinal (GI) based on the esophageal and stomach contractions/fluctuation. pH/impedance sensors will monitor the infection prevention effectiveness and be able to propose an accelerated feeding protocol from all aspects – optimal recovery of the patient with minimum exposure to gastric aspiration infection. The system, with its sophisticated AI algorithm, will demonstrate in a real time, better infection prevention, optimal feeding and optimal ventilation
Company’s Keywords:
publications
<1
<
<
Your request has been submitted successfully.
Own or work here?